Skip to main content
Topas Therapeutics GmbH

Falkenried 88, Haus A
20251 Hamburg GERMANY

+49 40 302089010
info@topas-therapeutics.com

Transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology

About Topas

Topas Therapeutics is advancing a highly differentiated and versatile approach to establish immune tolerance in autoimmune and immune-mediated diseases. Our lead candidate, TPM502, is preparing for a global Phase 2b clinical trial in celiac disease patients.

Topas Particle Conjugates, our proprietary, antigen-coupled nanoparticle platform technology, target liver sinusoidal endothelial cells to prompt anti-inflammatory immune responses and drive T cells toward tolerance. In the company’s Phase 2a study in celiac disease patients, TPM502 demonstrated a significant reduction of the inflammatory responses to gluten and long-lasting phenotypic changes to gliadin-specific T cells, with a favorable safety and tolerability profile that was maintained throughout the study period. This initial clinical proof of concept for our technology and its potential to address a broad spectrum of indications, positions us to deliver significant therapeutic benefits to patients.

Read More

The Challenge

Current autoimmune disease treatment relies predominantly on symptomatic relief, with limited disease-modifying effects and considerable risk of immune suppression.

Current
Treatments

Autoimmune diseases, like celiac disease, multiple sclerosis or pemphigus vulgaris, result when the immune system is overactive and attacks its own tissues. Current treatments for these diseases are predominantly immunosuppressant agents, which provide symptomatic relief but do not target the underlying molecular mechanisms, resulting in limited disease-modifying effects. These therapies come with significant long-term side effects and, due to their untargeted and immunosuppressive nature, compromise the body’s defense mechanisms.

TOPAS Solution

Our reproducible and versatile nanoparticle technology represents a revolutionary approach aiming to achieve disease-modifying effects.

Topas’ antigen-specific proprietary nanoparticle technology leverages the natural tolerogenic power of the liver.

These nanoparticles, known as Topas Particle Conjugates (TPCs), carry disease-related peptide epitopes and are engineered for targeted delivery into the liver sinusoidal endothelial cells (LSECs). A key advantage is that our TPCs offer a versatile mechanism to conjugate and combine immunogenic peptides of choice. This targeted approach induces antigen-specific tolerance, ensuring rapid clearance from circulation and preventing undesired systemic and immune reactions.

Tolerance induction by the LSECs is designed to produce a robust, long-lasting natural immunomodulation through the induction of regulatory T cells (Tregs). Tregs are crucial for maintaining immune tolerance, thereby reducing the likelihood of adverse immune responses. A stable population of Tregs equips the body to manage immune challenges more effectively, leading to fewer inflammatory episodes and improved overall health.

We have successfully advanced two programs into clinical development based on our proprietary TPC technology. Results from our Phase 2a study in celiac disease provided clinical proof of concept that TPM502 induces targeted, antigen-specific tolerogenic effects in patients. The persistence of TPM502-induced effects throughout the study period, supports our platform’s application in diverse disease conditions, potentially leading to substantial therapeutic benefits for patients with currently limited options.

Access the factsheet on our Phase 2a clinical trial in celiac disease here.

LEARN MORE ABOUT OUR PIPELINE

Upcoming Events

BIO 2025: BIO International Convention

Boston, MA

16-19 June 2025

TOPAS
News

Contact Us Here